This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to carry out a systematic review of the published evidence of height-screening programmes of children aged 4 to 11 years. A secondary aim was to examine the cost-effectiveness of a height screening programme in children of primary-school age.
Interventions
The screening for short stature was performed at school entry, age five. A specific method for height measurement was not reported. Rather, multiple available approaches were considered. The screening programme was compared with no screening.
Location/setting
UK/school.
Methods

Analytical approach:
This economic evaluation modelled a hypothetical cohort of 594,000 children (the number of five-year-old children in England and Wales). A lifetime horizon was considered. The authors stated that the analysis was carried out from the perspective of the National Health Service (NHS).
Effectiveness data:
The clinical data were derived from a systematic review of the literature, which identified the relevant clinical sources of data for the diagnostic yield of the screening programme. The search was carried out on electronic databases and was supplemented by contact with clinical experts and a review of the reference lists of the articles retrieved. Unpublished sources of data were also searched. All types of studies, except case reports, were included in the review. The clinical data were combined narratively. The key clinical outcome was the diagnostic yield of the screening in identifying heightrelated conditions, particularly growth-hormone deficiency and Turner syndrome.
Monetary benefit and utility valuations:
The utility valuations were derived from the literature and were augmented by estimates from an expert clinical panel. Other details were not provided.
Measure of benefit:
Quality-adjusted life-years (QALYs) were used as the summary benefit measure, which was combined with costs. The
